Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Stargardt Patient Treated With Retinal Pigment Epithelial Cells

Published: Friday, July 13, 2012
Last Updated: Friday, July 13, 2012
Bookmark and Share
Patient injected with 100,000 RPE cells at Wills Eye Institute.

Advanced Cell Technology, Inc. announced treatment of the fourth patient, the first in the second patient cohort, in its U.S. clinical trial for Stargardt's Macular Dystrophy (SMD).

The surgery was performed on Wednesday, July 11 at Wills Eye Institute in Philadelphia, by a surgical team lead by Carl D. Regillo, MD, FACS, director of the Wills Eye Clinical Retina Research Unit, attending surgeon in the Wills Eye Retina Service at the Wills Eye Institute, and professor of ophthalmology at Thomas Jefferson University. In keeping with trial protocol, the patient was injected with 100,000 human embryonic stem cell-derived retinal pigment epithelial (RPE) cells, as compared with the 50,000 cell dose used in the three patients of the first cohort. The outpatient transplantation surgery was performed successfully and the patient is recovering uneventfully.

"It is very gratifying to have second cohort, higher-dosage patient treatment underway in our U.S. clinical trial for SMD," commented Gary Rabin, chairman and CEO of ACT. "We are also pleased to be working with Dr. Regillo and his team at Wills Eye Institute, a truly first-class institution that is ranked as one of the best ophthalmology hospitals in the country by U.S. News & World Report."

Initiated in July of last year, the Phase I/II trial is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with SMD at 12 months, the study's primary endpoint. It will involve a total of 12 patients, with cohorts of three patients each in an ascending dosage format. As part of its RPE clinical program, the company is concurrently conducting a clinical trial for dry age-related macular degeneration and second trial for SMD in the United Kingdom.

"Doubling the cell dosage marks an important milestone in our clinical programs," said Robert Lanza, MD, ACT's chief scientific officer. "We look forward to continued progress and safety findings in the coming months, in both our U.S. and European trials."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Positive Safety Results for Macular Degeneration Treatment
Phase 1/2 clinical trials of RPE cells for the treatment of dry age-related macular degeneration and Stargardt’s macular degeneration show positive long term safety results and signs of visual improvement.
Thursday, October 16, 2014
ACT Issued Broad Patent for Human RPE Cells
New Australian patent covers human RPE cells made from range of pluripotent stem cells, including both embryonic stem cells and iPS cells.
Tuesday, July 31, 2012
ACT Treats 10th Patient in Embryonic Stem Cell Trials for Macular Degeneration
Third Stargardt's patient in EU trial treated with RPE cells derived from human embryonic Stem Cells at Moorfields Eye Hospital in London.
Monday, July 30, 2012
ACT Announces Europe's First Human Embryonic Stem Cell Transplant in Patient with Stargardt's Disease
Moorfields Eye Hospital in London initiates clinical trial using hESC-derived RPE cells.
Monday, January 23, 2012
Leading Eye Institute to Participate in ACT's Embryonic Stem Cell Clinical Trial
Wills Eye Institute receives IRB approval to treat dry-AMD using ACT's hESC-derived retinal pigment epithelial (RPE) cells.
Tuesday, January 17, 2012
Advanced Cell Technology's CEO Says Markets Are Just Starting to Appreciate the Significance of Their Stem Cell Derived Treatments
Several key announcements have pushed Advanced Cell Technology's stock from just under a nickel in late November to an intraday high of $.20 during Wednesday's session and volume has made it apparent that a growing crowd of day traders momentum players have now joined biotech investors in cheering on the small biotech.
Friday, December 10, 2010
ACT Receives FDA Clearance for the First Clinical Trial Using Embryonic Stem Cells to Treat Macular Degeneration
Company to commence a Phase I/II clinical trial at multiple centers.
Wednesday, November 24, 2010
NIH Approves Advanced Cell Technology’s Stem Cell Line for Federal Funding
Access to federal funding could accelerate clinical development.
Monday, June 14, 2010
ACT Files IND With FDA For First Human Clinical Trial Using Embryonic Stem Cells to Treat Eye Disease
The Phase I/II trial will be an open-label study designed to determine the safety and tolerability of the RPE cells following sub-retinal transplantation.
Thursday, November 26, 2009
Embryonic Stem Cells to Treat Eye Disease - ACTC Advanced Cell Technology Files IND with FDA
Advanced Cell Technology files IND with FDA for first human clinical trial using embryonic stem cells to treat eye disease.
Monday, November 23, 2009
Functional Vasculature Generated from Advanced Cell Technology’s Human Embryonic Stem Cells
Hemangioblasts form multilayered blood vessels with functional smooth muscle; could provide an inexhaustible source of cells to treat vascular disease.
Tuesday, January 06, 2009
Advanced Cell Technology and CHA Biotech Form new International Stem Cell Company
The new company; Allied Cell Technology; will develop human blood cells and other clinical therapies based on ACTC’s hemangioblast cell technology.
Tuesday, December 02, 2008
Clinical-Scale Generation of Functional Red Blood Cells from Human Embryonic Stem Cells
ACT reports that it is feasible to differentiate and mature hESCs into functional oxygen-carrying RBCs under conditions suitable for scale-up.
Wednesday, August 20, 2008
Advanced Cell Technology Demonstrates Generation of Functional Hepatocytes from Human Embryonic Stem Cells
The research signifies a step towards the efficient generation of hepatocytes for use in regenerative medicine and drug discovery.
Friday, February 22, 2008
Advanced Cell Technology Announces Creation of Human Embryonic Stem Cell Lines without the Destruction of Embryos
Breakthrough approach improves efficiency to levels reported in the conventional stem cell derivation techniques.
Friday, January 11, 2008
Scientific News
The Mending Tissue - Cellular Instructions for Tissue Repair
NUS-led collaborative study identifies universal mechanism that explains how tissue shape regulates physiological processes such as wound healing and embryo development.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
iPS Cells Discover Drug Target for Muscle Disease
Researchers have designed a model that reprograms fibroblasts to the early stages of their differentiation into intact muscle cells in a step towards a therapeutic for Duchenne muscular dystrophy.
Engineered Hot Fat Implants Reduce Weight Gain
Scientists at UC Berkeley have developed a novel way to engineer the growth and expansion of energy-burning “good” fat, and then found that this fat helped reduce weight gain and lower blood glucose levels in mice.
Transplanted Stem Cells Can Benefit Retinal Disease Sufferers
Tests on animal models show that MSCs secrete growth factors that suppress causes of diabetic retinopathy and macular degeneration.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Team Finds Early Inflammatory Response Paralyzes T Cells
Findings could have enormous implications for immunotherapy, autoimmune disorders, transplants and other aspects of immunity.
Early Detection of Lung Cancer
The University of Manchester has signed a collaboration agreement with Abcodia to perform proteomics studies on a cohort of non-small cell lung cancer cases from the UKCTOCS biobank, with the aim of discovering new blood-based biomarkers for earlier detection of the disease.
Researchers Identify Drug Candidate for Skin, Hair Regeneration
Formerly undiscovered role of protein may lead to the development of new medications that stimulate hair and skin regeneration in trauma or burn victims.
Basis for New Treatment Options for a Fatal Leukemia in Children Revealed
Detailed molecular analyses allow new insights into the function of tumour cells and options for new treatments.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!